ALMINOPROFEN

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H17NO2
Molecular Weight	219.2796
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1

InChI

InChIKey=FPHLBGOJWPEVME-UHFFFAOYSA-N

InChI=1S/C13H17NO2/c1-9(2)8-14-12-6-4-11(5-7-12)10(3)13(15)16/h4-7,10,14H,1,8H2,2-3H3,(H,15,16)

HIDE SMILES / InChI

Molecular Formula	C13H17NO2
Molecular Weight	219.2796
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9933032
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/2787705

Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. It has anti-inflammatory properties different from the classical NSAID. Alminoprofen possesses both antiphospholipase A2 (PLA2) activity and anti-cycloxygenase (COX) activity.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-2 196 Target ID: CHEMBL230 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9933032	Inhibitor 8297
Secretory phospholipase A2, Homo sapiens 3 Target ID: Secretory phospholipase A2, Homo sapiens Sources: http://www.ncbi.nlm.nih.gov/pubmed/9933032	Inhibitor 8297
Cyclooxygenase-1 127 Target ID: CHEMBL221 Sources: http://www.genome.jp/dbget-bin/www_bget?D01513	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: http://www.ndrugs.com/?s=minalfen	Palliative		Approved 8429	Minalfen Approved Use Indications: inflammation, pain
Inflammation 102 Sources: http://www.ndrugs.com/?s=minalfen	Primary		Approved 8429	Minalfen Approved Use Indications: inflammation, pain

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

In rheumatoid arthritis and spondylosis deformans - 200 mg (three times a day) repeated dose for 5 days.

Route of Administration: Oral

In Vitro Use Guide

Alminoprofen (10(-6)-10(-4) M) inhibited dose-dependently the chemotaxis of leukocytes induced by chemotactic factors from guinea pig neutrophils stimulated with sodium urate crystals.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:28:08 GMT 2023` Edited by `admin` on `Fri Dec 15 15:28:08 GMT 2023`
Record UNII	0255AHR9GJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALMINOPROFEN

Official Name

English

ALMINOPROFEN [MI]

Common Name

English

alminoprofen [INN]

Common Name

English

P-((2-METHYLALLYL)AMINO)HYDRATROPIC ACID

Common Name

English

ALMINOPROFEN [MART.]

Common Name

English

MINALFEN

Brand Name

English

Alminoprofen [WHO-DD]

Common Name

English

ALMINOPROFEN [JAN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM01AE16